A Phase Ib/II Open-label Study of AMO959 With Lutetium (177Lu) Vipivotide Tetraxetan (AAA617) in Combination With ARPI in Adult Participants With PSMA
A phase 1/2 trial of Enzalutamide, Abiraterone acetate in prostate cancer, run by Novartis Pharmaceuticals, now recruiting.
Overview
A Phase Ib/II Open-label Study of AMO959 With Lutetium (177Lu) Vipivotide Tetraxetan (AAA617) in Combination With ARPI in Adult Participants With PSMA-positive mCRPC is a phase 1/2 interventional study registered as NCT07226986 by Novartis Pharmaceuticals, with 123 participants planned, started 2025-12-05 and due to reach its primary completion in 2028-07-10. Interventions recorded: AMO959, AAA617, Enzalutamide, Abiraterone. Conditions listed: PSMA-positive Metastatic Castration Resistant Prostate Cancer (mCRPC) With Prior Exposure to One Prior ARPI Who Are Candidates for Taxane-based Chemotherapy. No results are recorded here; the registry entry is the source.
Similar pages
not linked directly; found by shared links- TrialAn Open-label Study of JSB462 (Luxdegalutamide) in Combination With Abiraterone in Adult Male Patients With Metastatic Hormone-sensitive Prostate Canc
Shares Enzalutamide, Abiraterone acetate, Novartis, Prostate cancer.
- TrialA Study of ARV-766 Given by Mouth in Men With Metastatic Prostate Cancer
Shares Abiraterone acetate, Novartis, Prostate cancer.
- TrialTulmiSTAR-02: A Phase I/II Open-label Study of Tulmimetostat in Combination With Darolutamide vs. Darolutamide, and Tulmimetostat With Abiraterone in
Shares Abiraterone acetate, Novartis, Prostate cancer.
- TrialA Study of Tulmimetostat DZR123 (CPI-0209) in Patients With Advanced Solid Tumors and Lymphomas
Shares Enzalutamide, Novartis, Prostate cancer.
- TrialA Study to Test Inavolisib Treatment in Participants With Metastatic Castration-Resistant Prostate Cancer
Shares Enzalutamide, Abiraterone acetate, Prostate cancer.
- TrialAbiraterone, Enzalutamide, or Apalutamide in Castrate-sensitive Prostate Cancer.
Shares Enzalutamide, Abiraterone acetate, Prostate cancer.
- TrialStudy of SX-682 Plus Enzalutamide in Men With ARPI-Resistant Metastatic Castration Resistant Prostate Cancer
Shares Enzalutamide, Prostate cancer.
- TrialThe Study of 177Lu-TLX591 Plus SOC Versus SOC Alone in Patients With mCRPC (ProstACT Global)
Shares Enzalutamide, Abiraterone acetate, Prostate cancer.